Benzinga | Dec 9, 2020 05:36AM EST

Amryt Group Announced Marketing Authorisation Approval for Lojuxta in Brazil

Amryt (NASDAQ:AMYT) is pleased to announce that the Amryt group has received marketing authorisation approval from the Brazilian Health Regulatory Agency ("ANVISA"/Agencia Nacional De Vigilancia Sanitaria) for Lojuxta® (lomitapide).

Lojuxta® has been approved as an adjunct to a low-fat diet and other lipid-lowering treatments, with or without low density lipoprotein (LDL) apheresis, to reduce low-density lipoprotein cholesterol (LDL-C) in adult patients with homozygous familial hypercholesterolaemia (HoFH).

Dr Joe Wiley, CEO of Amryt Pharma, commented today: "We are pleased that ANVISA has recognised the significant unmet medical need of patients in Brazil suffering from HoFH and have approved marketing authorisation for Lojuxta® to treat adults with this condition. Today's news is another milestone in executing our strategy to make Lojuxta® available to HoFH patients in need globally."